These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

291 related items for PubMed ID: 24504791

  • 1. Concordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma.
    Bass JK, Huang J, Onar-Thomas A, Chang KW, Bhagat SP, Chintagumpala M, Bartels U, Gururangan S, Hassall T, Heath JA, McCowage G, Cohn RJ, Fisher MJ, Robinson G, Broniscer A, Gajjar A, Gurney JG.
    Pediatr Blood Cancer; 2014 Apr; 61(4):601-5. PubMed ID: 24504791
    [Abstract] [Full Text] [Related]

  • 2. A comparison of the Muenster, SIOP Boston, Brock, Chang and CTCAEv4.03 ototoxicity grading scales applied to 3,799 audiograms of childhood cancer patients treated with platinum-based chemotherapy.
    Clemens E, Brooks B, de Vries ACH, van Grotel M, van den Heuvel-Eibrink MM, Carleton B.
    PLoS One; 2019 Apr; 14(2):e0210646. PubMed ID: 30763334
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma.
    Gurney JG, Bass JK, Onar-Thomas A, Huang J, Chintagumpala M, Bouffet E, Hassall T, Gururangan S, Heath JA, Kellie S, Cohn R, Fisher MJ, Panandiker AP, Merchant TE, Srinivasan A, Wetmore C, Qaddoumi I, Stewart CF, Armstrong GT, Broniscer A, Gajjar A.
    Neuro Oncol; 2014 Jun; 16(6):848-55. PubMed ID: 24414535
    [Abstract] [Full Text] [Related]

  • 4. Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy (ACCL05C1): A Report From the Children's Oncology Group.
    Knight KR, Chen L, Freyer D, Aplenc R, Bancroft M, Bliss B, Dang H, Gillmeister B, Hendershot E, Kraemer DF, Lindenfeld L, Meza J, Neuwelt EA, Pollock BH, Sung L.
    J Clin Oncol; 2017 Feb; 35(4):440-445. PubMed ID: 27937095
    [Abstract] [Full Text] [Related]

  • 5. Applications of the Grading Scales for the Detection of Ototoxicity in Children after Treatment of Neuroblastoma and Extracranial Germinal Tumor.
    Polski B, Sosnowska-Sienkiewicz P, Szydłowski J, Januszkiewicz-Lewandowska D.
    Audiol Neurootol; 2023 Feb; 28(1):32-42. PubMed ID: 36191558
    [Abstract] [Full Text] [Related]

  • 6. Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales--a report from the Children's Oncology Group.
    Landier W, Knight K, Wong FL, Lee J, Thomas O, Kim H, Kreissman SG, Schmidt ML, Chen L, London WB, Gurney JG, Bhatia S.
    J Clin Oncol; 2014 Feb 20; 32(6):527-34. PubMed ID: 24419114
    [Abstract] [Full Text] [Related]

  • 7. Early cisplatin induced ototoxicity profile may predict the need for hearing support in children with medulloblastoma.
    Lafay-Cousin L, Purdy E, Huang A, Cushing SL, Papaioannou V, Nettel-Aguirre A, Bouffet E.
    Pediatr Blood Cancer; 2013 Feb 20; 60(2):287-92. PubMed ID: 23002030
    [Abstract] [Full Text] [Related]

  • 8. SOD2 genetic variant associated with treatment-related ototoxicity in cisplatin-treated pediatric medulloblastoma.
    Brown AL, Lupo PJ, Okcu MF, Lau CC, Rednam S, Scheurer ME.
    Cancer Med; 2015 Nov 20; 4(11):1679-86. PubMed ID: 26400460
    [Abstract] [Full Text] [Related]

  • 9. Hearing evaluation of patients with head and neck cancer: Comparison of Common Terminology Criteria for Adverse Events, Brock and Chang adverse event criteria in patients receiving cisplatin.
    Colevas AD, Lira RR, Colevas EA, Lavori PW, Chan C, Shultz DB, Chang KW.
    Head Neck; 2015 Aug 20; 37(8):1102-7. PubMed ID: 24737682
    [Abstract] [Full Text] [Related]

  • 10. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma.
    Fouladi M, Chintagumpala M, Ashley D, Kellie S, Gururangan S, Hassall T, Gronewold L, Stewart CF, Wallace D, Broniscer A, Hale GA, Kasow KA, Merchant TE, Morris B, Krasin M, Kun LE, Boyett JM, Gajjar A.
    J Clin Oncol; 2008 Aug 01; 26(22):3749-55. PubMed ID: 18669462
    [Abstract] [Full Text] [Related]

  • 11. Ototoxicity evaluation in medulloblastoma patients treated with involved field boost using intensity-modulated radiation therapy (IMRT): a retrospective review.
    Vieira WA, Weltman E, Chen MJ, da Silva NS, Cappellano AM, Pereira LD, Gonçalves MI, Ferrigno R, Hanriot RM, Nadalin W, Odone Filho V, Petrilli AS.
    Radiat Oncol; 2014 Jul 21; 9():158. PubMed ID: 25041714
    [Abstract] [Full Text] [Related]

  • 12. DNA methylation of a novel PAK4 locus influences ototoxicity susceptibility following cisplatin and radiation therapy for pediatric embryonal tumors.
    Brown AL, Foster KL, Lupo PJ, Peckham-Gregory EC, Murray JC, Okcu MF, Lau CC, Rednam SP, Chintagumpala M, Scheurer ME.
    Neuro Oncol; 2017 Oct 01; 19(10):1372-1379. PubMed ID: 28444219
    [Abstract] [Full Text] [Related]

  • 13. Carboplatin and ototoxicity: hearing loss rates among survivors of childhood medulloblastoma.
    Musial-Bright L, Fengler R, Henze G, Hernáiz Driever P.
    Childs Nerv Syst; 2011 Mar 01; 27(3):407-13. PubMed ID: 20931205
    [Abstract] [Full Text] [Related]

  • 14. The cochlear dose and the age at radiotherapy predict severe hearing loss after passive scattering proton therapy and cisplatin in children with medulloblastoma.
    Abu-Arja MH, Brown AL, Su JM, Okcu MF, Lindsay HB, McGovern SL, McAleer MF, Grosshans DR, Chintagumpala MM, Paulino AC.
    Neuro Oncol; 2024 Oct 03; 26(10):1912-1920. PubMed ID: 38916058
    [Abstract] [Full Text] [Related]

  • 15. Incidence of platinum-induced ototoxicity in pediatric patients in Quebec.
    Peleva E, Emami N, Alzahrani M, Bezdjian A, Gurberg J, Carret AS, Daniel SJ.
    Pediatr Blood Cancer; 2014 Nov 03; 61(11):2012-7. PubMed ID: 24976616
    [Abstract] [Full Text] [Related]

  • 16. Prevalence and risk factors for cisplatin-induced hearing loss in children, adolescents, and young adults: a multi-institutional North American cohort study.
    Moke DJ, Luo C, Millstein J, Knight KR, Rassekh SR, Brooks B, Ross CJD, Wright M, Mena V, Rushing T, Esbenshade AJ, Carleton BC, Orgel E.
    Lancet Child Adolesc Health; 2021 Apr 03; 5(4):274-283. PubMed ID: 33581749
    [Abstract] [Full Text] [Related]

  • 17. Hearing Loss Risk in Pediatric Patients Treated with Cranial Irradiation and Cisplatin-Based Chemotherapy.
    Cohen-Cutler S, Wong K, Mena V, Sianto K, Wright MA, Olch A, Orgel E.
    Int J Radiat Oncol Biol Phys; 2021 Aug 01; 110(5):1488-1495. PubMed ID: 33677052
    [Abstract] [Full Text] [Related]

  • 18. Practical grading system for evaluating cisplatin ototoxicity in children.
    Chang KW, Chinosornvatana N.
    J Clin Oncol; 2010 Apr 01; 28(10):1788-95. PubMed ID: 20194861
    [Abstract] [Full Text] [Related]

  • 19. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
    van As JW, van den Berg H, van Dalen EC.
    Cochrane Database Syst Rev; 2014 Jul 01; (7):CD009219. PubMed ID: 24984156
    [Abstract] [Full Text] [Related]

  • 20. Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity.
    Huang E, Teh BS, Strother DR, Davis QG, Chiu JK, Lu HH, Carpenter LS, Mai WY, Chintagumpala MM, South M, Grant WH, Butler EB, Woo SY.
    Int J Radiat Oncol Biol Phys; 2002 Mar 01; 52(3):599-605. PubMed ID: 11849779
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.